Evidence map›Paper›PMID 30714523›Full record

ReviewCurrent drug delivery2019

Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.

Afzal Hussain, Sima Singh, Sabya Sachi Das, Keshireddy Anjireddy, Subramanian Karpagam, Faiyaz Shakeel

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Crystal Growth and Kinetic Behaviour ofOxidative medicine and cellular longevity · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Afzal HussainFaculty of Pharmacy, S. Sinha College, Aurangabad-824101, Bihar, India.
Sima SinghDepartment of Pharmaceutical Sciences and technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.
Sabya Sachi DasDepartment of Pharmaceutical Sciences and technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.
Keshireddy AnjireddyDepartment of Chemistry, VIT University, Vellore 632014, Tamilnadu, India.
Subramanian KarpagamDepartment of Chemistry, VIT University, Vellore 632014, Tamilnadu, India.
Faiyaz ShakeelDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder as a major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover, the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO.

Indexed as

AnimalsAntitubercular AgentsDrug CarriersHumansInfection ControlMycobacterium tuberculosisNanomedicineTuberculosis, PulmonaryTuberculosis VaccinesAntitubercular AgentsDrug CarriersTuberculosis VaccinesClinical therapydiagnosisnanomedicinepathogenesisreview.Tuberculosis

Identifiers

PMID30714523
PMCPMC6637229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.